Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC
Regeneron is conducting a study to evaluate the efficacy and safety of ubamatamab and REGN7075 in advanced/metastatic NSCLC.
Asset / Drug
Drug and asset intelligence for ubamatamab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.